Contact Us
Drug Search Results
More Filters [+]

Artesunate

Alternative Names: artesunate
Latest Update: 2025-01-13
Latest Update Note: Clinical Trial Update

Product Description

Artesunate injection is used to treat severe malaria. This medicine is also used together with other medicines (eg, 8-aminoquinoline medicine) to treat severe malaria caused by Plasmodium ovale or Plasmodium vivax. (Sourced from: https://www.mayoclinic.org/drugs-supplements/artesunate-intravenous-route/side-effects/drg-20489625?p=1)

Mechanisms of Action: NOTCH Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral,Intravenous

FDA Designation: None *

Approval Status: Approved

Approved Countries: Bangladesh | Belgium | Brazil | China | Colombia | Croatia | Czech | Egypt | Estonia | European Medicines Agency | Finland | Germany | Greece | Hungary | Iceland | India | Indonesia | Ireland | Italy | Latvia | Lithuania | Malaysia | Netherlands | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Slovakia | Slovenia | South Africa | Sweden | Thailand | Ukraine | United Kingdom | United States | Vietnam

Approved Indications: Malaria | Malaria, Vivax

Known Adverse Events: Malaria | Hemoglobinuria

Company: Ministry of Health
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Artesunate

Countries in Clinic: Bangladesh, Burkina Faso, Cambodia, Congo, Gambia, Guinea, Kenya, Korea, Niger, Nigeria, Rwanda, Tanzania, United States

Active Clinical Trial Count: 11

Highest Development Phases

Phase 3: Malaria, Falciparum

Phase 2: Anal Cancer|COVID-19|Carcinoma in Situ|Cervical Cancer|Friedreich Ataxia|Malaria|Papillomavirus Infections|Squamous Cell Carcinoma|Squamous Intraepithelial Lesions of the Cervix|Uterine Cancer|Uterine Cervical Dysplasia|Vulvar Cancer|Vulvar Diseases

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
ART-AIN IIB-2

P2

Recruiting

Carcinoma in Situ|Squamous Cell Carcinoma|Papillomavirus Infections|Squamous Intraepithelial Lesions of the Cervix|Anal Cancer

2025-12-31

LCCC2236

P1

Recruiting

Uterine Cervical Dysplasia|Cervical Cancer|Uterine Cancer

2025-12-01

ART-VIN IIB

P2

Recruiting

Vulvar Diseases|Papillomavirus Infections|Vulvar Cancer

2025-12-01

ART-CIN_IIB

P2

Recruiting

Uterine Cervical Dysplasia|Cervical Cancer|Uterine Cancer|Papillomavirus Infections

2025-07-31

Recent News Events

Date

Type

Title

04/26/2024

News Article

 Fosun Pharma's Self-developed Artemisinin Medicines Inject New Impetus to Malaria Prevention and Treatment in Africa

03/18/2024

News Article

 Dupharma Biotech forms R&D partnerships for new therapies

03/07/2024

News Article

 HKBU research suggests potential of artemisinin derivative in treating human obesity

12/14/2023

News Article

 Fosun Pharma's Global Multi-Center Phase III Clinical Trial Project for A New Antimalarial Drug Receives 500 Million Japanese Yen Investment from GHIT Fund to Jointly Improve the Global Accessibility of Antimalarial Drugs

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions